 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
GlycoMimetics
GLYC
conference date: 10-Q issued, no press release or conference, November 13, 2024
GlycoMimetics Could Surge if Q1 Data Readout is Positive [November 11, 2022 at Seeking Alpha]
I Like GLYC [March 16, 2022 at Seeking Alpha]
Older articles can be found below the summary table
Analyst Call Notes by William P. Meyers |
|||
| 2024 | |||
| GlycoMimetics Q1 2024 10-Q |
GlycoMimetics Q2 2024 10-Q |
GlycoMimetics Q3 2024 10-Q |
|
May 9, 2024 |
Aug. 8, 2024 |
Nov. 13, 2024 |
|
| 2023 | |||
| GlycoMimetics Q1 2023 |
GlycoMimetics Q2 2023 |
GlycoMimetics Q3 2023 |
GlycoMimetics Q4 2023 |
May 3, 2023 |
Aug. 2, 2023 |
Nov. 3, 2023 |
Mar. 27, 2024 |
| 2022 | |||
| GlycoMimetics Q1 2022 |
GlycoMimetics Q2 2022 |
GlycoMimetics Q3 2022 |
GlycoMimetics Q4 2022 |
April 28, 2022 |
Aug. 3, 2022 |
Nov. 9, 2022 |
March 29, 2023 |
| 2021 | |||
| GlycoMimetics Q1 2021 |
GlycoMimetics Q2 2021 |
GlycoMimetics Q3 2021 |
GlycoMimetics Q4 2021 |
May 3, 2021 |
Aug. 5, 2021 |
Nov. 2, 2021 |
March 3, 2022 |
| 2020 | |||
| GlycoMimetics Q1 2020 |
GlycoMimetics Q2 2020 |
GlycoMimetics Q3 2020 |
GlycoMimetics Q4 2020 |
May 1, 2020 |
July 31, 2020 |
Nov. 6, 2020 |
March 2, 2021 |
| 2019 | |||
| GlycoMimetics Q1 2019 |
GlycoMimetics Q2 2019 |
GlycoMimetics Q3 2019 |
GlycoMimetics Q4 2019 |
May 2, 2019 |
August 1, 2019 |
Nov. 7, 2019 |
Feb. 28, 2020 |
2018 |
|||
| GlycoMimetics Q4 2018 |
|||
May 3, 2018 |
August 10, 2018 |
Nov. 2, 2018 |
March 6, 2019 |
2017 |
|||
May 18, 2017 |
Nov. 8, 2017 |
March 6, 2018 |
|
2016 |
|||
05/04/2016 |
08/04/2016 |
11/04/2016 |
03/01/2017 |
2015 |
|||
tba |
8/6/2015 |
11/12/2015 |
2/29/2016 |
GlycoMimetics' Possible Rivipansel Revival [October 13, 2020 at Seeking Alpha]
GlycoMimetics' Focus Is On AML Therapy [April 17, 2020 at Seeking Alpha]
GlycoMimetics: Still Potential In AML Therapy [September 5, 2019 at Seeking Alpha]
GlycoMimetics Drug Rivipansel Fails Phase 3 Trial [August 2, 2019]
Biotech Bargain Basement: GlycoMimetics [January 8, 2019]
GlycoMimetics: Buy This Dip [April 4, 2018]
GlycoMimetics Remains Undervalued After Leukemia Data Release [June 14, 2017 at Seeking Alpha]
GlycoMimetics: Undercovered with Catalysts Coming [June 9, 2016 at Seeking Alpha]
GlycoMimetics GMI-1271 Effective in Phase I Leukemia Trial [May 19, 2016]
GlycoMimetics Novel Therapeutic Approach [February 5, 2016 at Seeking Alpha]
I Buy GlycoMimetics [April 6, 2015 at Dissecting the Bull]
GlycoMimetics and Pfizer Initiate Phase 3 Rivipansel Trial [June 23, 2015]
FDA Grants Orphan Drug Status to GMI-1271 [May 14, 2015]
GlycoMimetics (GLYC) is a clinical-stage developer of glycoprotein based therapies, including rivipansel and uproleselan.
More Analyst Conference Notes:
| AGEN |
| AGIO |
| ALNY |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BLRX |
| BLUE |
| BMY |
| CDTX |
| CLDX |
| FATE |
| GILD |
| ILMN |
| INO |
| IONS |
| INCY |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| SAGE |
| SYRS |
| TSVT |
| VRTX |
| VSTM |
| WBA |
Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is investment journalism, not financial advice.
Copyright 2024 William P. Meyers